Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) EBITDA
Incyte Corporation's EBITDA for fiscal 2025 was $1.6B, up 967.7% from $150.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.9B. Over the past ten years it has ranged from −$211.9M (fiscal 2020) to $1.6B (fiscal 2025) — the current reading is the highest in ten years. Incyte Corporation ranks 3rd of 617 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.6B | 967.73% |
| FY2024 | $150.6M | (78.58%) |
| FY2023 | $703.2M | 8.63% |
| FY2022 | $647.3M | 0.57% |
| FY2021 | $643.6M | — |
| FY2020 | −$211.9M | — |
| FY2019 | $456.5M | 147.86% |
| FY2018 | $184.2M | — |
| FY2017 | −$191.2M | — |
| FY2016 | $203.4M | 112.93% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $724.4M | 122.94% |
| Mar 2026 | $324.9M | (9.70%) |
| Dec 2025 | $359.8M | (23.04%) |
| Sep 2025 | $467.5M | (15.49%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| INCY Incyte Corporation | $1.9B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| GMAB Genmab A/S Sponsored ADR compare | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.1B |
| EXEL Exelixis, Inc. compare | $999.8M |
| ASND Ascendis Pharma A/S compare | $321.3M |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| INSM Insmed, Inc. compare | −$812.5M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on INCY
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement